Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteinuria-lowering effect of guideline-directed dapagliflozin plus ACEi/ARB in CKD with type 2 diabetes (China)
ChiCTR2200063026Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by Ruijin Hospital. Primary endpoints: 24h urine protein and blood glucose. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2200063026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063026.